Delcath Systems, Inc. Announces Positive Results from Independent Study of Liver-Directed Therapy for Patients with Uveal Melanoma

Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of a clinical study in the journal Therapeutic Advances in Medical Oncology. The publication, titled “Melanoma-specific survival of patients with uveal melanoma and liver metastases diagnosis between 2005 and 2021,” was based on an independent retrospective clinical study conducted by researchers at the University of Tübingen, Germany. The study demonstrates that first-line liver-directed therapies, including Delcath’s CHEMOSAT Hepatic Delivery System, significantly improve melanoma-specific survival (MSS) in patients with liver metastases from uveal melanoma compared to first-line systemic therapies.

Key findings of the research: